Paradigm Cancer Diagnostic (PCDx) lung cancer testing panels were recently expanded to also include 17 fusions, as well as EGFR and MET skipping events. The fusions include: ALK, AXL, BRAF, CCND1, FGFR1, FGFR2, FGFR3, MET, NGR1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS1, and THADA. The fusion panel may also be ordered as an add-on for any PCDx patients for standard five-day turnaround. Paradigm uses anchored PCR technology on RNA to detect known and novel fusions with high sensitivity using a tissue requirement of 4% or greater tumor content in a single core needle biopsy or fine needle aspirate. PCDx is a clinical-grade comprehensive sequencing test that covers DNA, RNA, fusions, and immunohistochemistry and interrogates the most actionable targets with a 5,000x average depth of coverage and delivers a report in five business days using the latest evidence with associations including associations to up to 87 different FDA approved therapies and 19 combinations.